Alx Oncology Holdings (ALXO) Receivables - Other (2019 - 2020)
Alx Oncology Holdings (ALXO) posted Receivables - Other of -$527000.0 for Q4 2020, down 200.0% sequentially from $527000.0 in Q3 2020, and up 34.94% YoY from -$390548.9 in Q1 2020.
Powered by 
Analysis
Alx Oncology Holdings (ALXO) Receivables - Other (2019 - 2020) Analysis & Trends
Alx Oncology Holdings has reported Receivables - Other for 2 years, with the latest figure at -$527000.0 in Q4 2020.
- Quarterly Receivables - Other rose 34.94% year-over-year to -$527000.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was -$686000.0 (changed N/A YoY) and the FY2020 annual result came in at -$536000.0, down 200.0% from the prior year.
- Receivables - Other declined to -$527000.0 in Q4 2020 per ALXO's latest filing, from $527000.0 in the prior quarter.
- Over five years, Receivables - Other peaked at $655000.0 in Q1 2020 and troughed at -$810000.0 in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Alx Oncology Holdings | 274.67 Mn | 274.67 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2020 | 527,000.00 |
| Jun 30, 2020 | 527,000.00 |
| Dec 31, 2019 | 500,000.00 |